Reference : A 5-Year Controlled Randomized Study of Prevention of Postmenopausal Trabecular Bone ...
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/125041
A 5-Year Controlled Randomized Study of Prevention of Postmenopausal Trabecular Bone Loss with Nasal Salmon Calcitonin and Calcium
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Meurmans, L. [> > > >]
Deroisy, Rita mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Jupsin, Isabelle mailto [Centre Hospitalier Universitaire de Liège - CHU > > Médecine de l'appareil locomoteur >]
Biquet, I. [> > > >]
Albert, Adelin mailto [Université de Liège - ULg > Département des sciences de la santé publique > Informatique médicale et biostatistique >]
Franchimont, P. [> > > >]
Aug-1994
European Journal of Clinical Investigation
24
8
565-9
Yes (verified by ORBi)
International
0014-2972
[en] The aim of this paper was to evaluate the long-term (5 years) efficacy of nasal salmon calcitonin in prevention of trabecular postmenopausal bone loss, which was a follow-up of a previously published study (3 years); a randomized, controlled group comparison. One hundred healthy postmenopausal women were randomly chosen from those (186) having completed the 3 year protocol. The 100 women were allocated to an additional 2 year period (total of 5 years) of treatment with either 500 mg d-1, 5 days week-1 of calcium or the same amount of calcium plus 50 IU d-1, 5 days per week of nasal salmon calcitonin, 87 (87%) women complied with the protocol throughout. The main outcome measures were the bone mineral density of the lumbar spine (1-BMD) (DPA) and biochemical parameters reflecting bone turnover (serum alkaline phosphatases, urinary calcium/creatinine and hydroxyproline/creatinine ratios). The women receiving calcium alone presented a significant decrease in 1-BMD after 6 months [-1.6 (0.5)%] [mean(SEM)] (P < 0.01) and this decrease remained significant after 36 months [-6.1(0.8)%] (P < 0.01) and until the end of the trial [-6.6(1.0)% at t60] (P < 0.01). In women receiving calcium and calcitonin, 1-BMD significantly increased after 36 months [+2(0.7%] (P < 0.01) and 42 months [+2.5(0.7)%] (P < 0.01 and was unchanged at the other times of investigation [+1.1 (1.1)% at t60] (NS). The evolution of BMD in the two groups was highly significantly different (P < 0.001) since the sixth month of the study and remained so until the end of the study.(ABSTRACT TRUNCATED AT 250 WORDS)
http://hdl.handle.net/2268/125041

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
A 5-Year Controlled Randomized Study of Prevention of Postmenopausal Trabecular Bone Loss with Nasal Salmon Calcitonin and Calcium.pdfPublisher postprint2.28 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.